Although we have not observed strong type-1 immune responses characterized by the induction of CD4+ Th1 cells and CD8+ T cells by HP-β-CD adjuvanted influenza vaccine, we are keen to investigate the mechanism of the adjuvant effect of HP-β-CD on influenza antigen in near future, as we conducted a human clinical trial, in which HP-β-CD was used as an adjuvant for seasonal 4-valent influenza vaccine (UMIN000028530). The gene discussed is CD4; the disease is influenza.